Detail akcie PAVmed Rg online

Business Summary: PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, PAVmed Inc revenues decreased 99% to $19K. Net loss applicable to common stockholders totaled $1.9M vs. income of $30.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from $2.62 to $0.25.